X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (3356) 3356
Book Review (720) 720
Newsletter (336) 336
Publication (128) 128
Book / eBook (43) 43
Newspaper Article (29) 29
Book Chapter (15) 15
Magazine Article (8) 8
Conference Proceeding (6) 6
Dissertation (3) 3
Web Resource (3) 3
Transcript (2) 2
Trade Publication Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
dermatology (2929) 2929
humans (2784) 2784
index medicus (2753) 2753
dermatologic agents (1744) 1744
formulae, receipts, prescriptions (1613) 1613
female (1455) 1455
male (1428) 1428
psoriasis (1346) 1346
dermatologic agents - therapeutic use (1276) 1276
adult (1059) 1059
middle aged (1023) 1023
skin (909) 909
psoriasis - drug therapy (885) 885
treatment outcome (805) 805
aged (578) 578
dermatologic agents - adverse effects (548) 548
dermatologic agents - administration & dosage (532) 532
care and treatment (508) 508
drug therapy (490) 490
animals (468) 468
analysis (463) 463
severity of illness index (392) 392
adolescent (389) 389
skin diseases (363) 363
therapy (337) 337
immunology (329) 329
double-blind (326) 326
young adult (296) 296
research (295) 295
medical research (294) 294
inflammation (286) 286
atopic dermatitis (285) 285
psoriasis - immunology (282) 282
efficacy (266) 266
antibodies, monoclonal - therapeutic use (265) 265
medicine, experimental (260) 260
child (258) 258
administration, topical (252) 252
infliximab (239) 239
allergy (236) 236
dermatitis (232) 232
health aspects (230) 230
skin - pathology (228) 228
mice (219) 219
eczema (218) 218
administration, cutaneous (211) 211
psoriasis - pathology (208) 208
skin - drug effects (203) 203
safety (202) 202
patients (197) 197
clinical trials (195) 195
dermatologic agents - pharmacology (195) 195
dermatitis, atopic - drug therapy (193) 193
immunosuppressive agents - therapeutic use (191) 191
quality of life (189) 189
retrospective studies (185) 185
disease (175) 175
etanercept (173) 173
double-blind method (172) 172
methotrexate (172) 172
cancer (171) 171
medicine & public health (171) 171
risk factors (168) 168
drug therapy, combination (166) 166
expression (164) 164
monoclonal antibodies (160) 160
rheumatoid-arthritis (160) 160
aged, 80 and over (159) 159
anti-inflammatory agents - therapeutic use (159) 159
time factors (159) 159
pharmacology & pharmacy (158) 158
t cells (155) 155
children (153) 153
corticosteroids (153) 153
reports (151) 151
medicine (148) 148
skin - immunology (147) 147
arthritis (146) 146
cytokines (144) 144
immunotherapy (144) 144
tumor necrosis factor-alpha - antagonists & inhibitors (144) 144
prospective studies (139) 139
calcitriol - analogs & derivatives (136) 136
management (136) 136
dermatology & venereal diseases (133) 133
drug administration schedule (133) 133
child, preschool (131) 131
acne (126) 126
chronic disease (124) 124
universities and colleges (123) 123
psoriasis - therapy (122) 122
research article (121) 121
drugs (120) 120
atopic-dermatitis (119) 119
pediatrics (119) 119
abridged index medicus (117) 117
cells (117) 117
follow-up studies (117) 117
quality-of-life (117) 117
keratinocytes (115) 115
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Gerstein Science - Stacks (31) 31
Collection Dvlpm't (Acquisitions) - Vendor file (3) 3
Online Resources - Online (3) 3
Lakeridge Health Sciences - Oshawa (2) 2
Collection Dvlpm't (Acquisitions) - Closed Orders (1) 1
Toronto East General Hospital - Stacks (1) 1
Trillium Health Centre - Stacks (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (3694) 3694
German (28) 28
French (20) 20
Spanish (12) 12
Italian (8) 8
Russian (8) 8
Japanese (4) 4
Danish (2) 2
Hungarian (2) 2
Norwegian (2) 2
Chinese (1) 1
Dutch (1) 1
Romanian (1) 1
Slovak (1) 1
Swedish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


PLoS ONE, ISSN 1932-6203, 12/2016, Volume 11, Issue 12, pp. e0167757 - e0167757
TNF-alpha has a central role in the development and maintenance of psoriatic plaques, and its serum levels correlate with disease activity. Anti-TNF-alpha... 
RHEUMATOID-ARTHRITIS | THERAPY | DENDRITIC CELLS | MULTIDISCIPLINARY SCIENCES | PHASE-III | DISEASE | NECROSIS-FACTOR-ALPHA | RANDOMIZED CONTROLLED-TRIAL | INFLIXIMAB | ETANERCEPT | GENE POLYMORPHISMS | Humans | Middle Aged | Tumor Necrosis Factor-alpha - blood | Anti-Inflammatory Agents - immunology | Male | Dermatologic Agents - therapeutic use | Monocytes - immunology | Infliximab - therapeutic use | Leukocytes, Mononuclear - immunology | Receptors, Tumor Necrosis Factor - blood | Tumor Necrosis Factor-alpha - immunology | Anti-Inflammatory Agents - therapeutic use | Antibodies - immunology | Adult | Female | Psoriasis - blood | Psoriasis - immunology | Adalimumab - immunology | Leukocytes, Mononuclear - drug effects | Psoriasis - drug therapy | Infliximab - immunology | Monocytes - drug effects | Adalimumab - therapeutic use | Etanercept - immunology | Antibodies - blood | Aged | Dermatologic Agents - immunology | Receptors, Tumor Necrosis Factor - immunology | Tumor Necrosis Factor-alpha - antagonists & inhibitors | Cohort Studies | Etanercept - therapeutic use | Drugs | Pathogenesis | infliximab | Antibodies | Amino acids | Leukocytes (mononuclear) | Systematic review | Cell adhesion & migration | Receptors | Etanercept | Lymphocytes | Surgery | Modulation | Peripheral blood mononuclear cells | Tumor necrosis factor-TNF | Life sciences | Drug dosages | Plaques | Immunoglobulins | Psoriasis | Cytokines | Dendritic cells | Dermatology | Inflammation | Dentistry | Tumor necrosis factor-α | Patients | Medicine | Serum levels | Monocytes | Rheumatoid arthritis | Morphology | Monoclonal antibodies | TNF inhibitors | Plasma levels | Index Medicus
Journal Article
Proceedings of the National Academy of Sciences of the United States of America, ISSN 0027-8424, 8/2006, Volume 103, Issue 31, pp. 11736 - 11741
We have demonstrated that cytokine thymic stromal lymphopoietin (TSLP), whose expression is rapidly induced upon keratinocyteselective ablation of retinoid X... 
T lymphocytes | Receptors | Ethanol | Vitamin D | Cytokines | Cholecalciferols | Keratinocytes | Skin | Mast cells | Inflammation | Retinoic acid receptor | Retinoid X receptor | Retinoic acid | Vitamin D receptor | retinoid X receptor | ALLERGIC INFLAMMATION | CELLS | MULTIDISCIPLINARY SCIENCES | skin | NUCLEAR RECEPTOR SUPERFAMILY | retinoic acid receptor | retinoic acid | GENE | ASTHMA | ABLATION | vitamin D receptor | 1,25-DIHYDROXYVITAMIN D-3 | MICE | ASSOCIATION | Skin - cytology | Retinoid X Receptor alpha - metabolism | Calcium - metabolism | Dermatologic Agents - administration & dosage | Humans | Calcitriol - adverse effects | Dermatologic Agents - adverse effects | Receptors, Calcitriol - genetics | Receptors, Retinoic Acid - genetics | Calcitriol - administration & dosage | Calcitriol - analogs & derivatives | Dermatitis, Atopic - chemically induced | Vitamins - immunology | Receptors, Retinoic Acid - agonists | Dermatitis, Atopic - immunology | Female | Cytokines - genetics | Dimerization | Skin - pathology | Cytokines - immunology | Retinoid X Receptor beta - metabolism | Vitamins - chemistry | Cells, Cultured | Retinoid X Receptor beta - genetics | Mice, Transgenic | Receptors, Retinoic Acid - metabolism | Keratinocytes - cytology | Receptors, Calcitriol - metabolism | Keratinocytes - immunology | Mice, Knockout | Retinoid X Receptor alpha - agonists | Vitamins - adverse effects | Animals | Retinoid X Receptor alpha - genetics | Mice | Dermatologic Agents - immunology | Administration, Topical | Retinoids - immunology | Skin - drug effects | Vitamins - administration & dosage | Calcitriol - immunology | Retinoid X Receptor beta - agonists | Physiological aspects | Causes of | Vitamin D3 | Atopic dermatitis | Tretinoin | Lymphocyte receptors | Genotype & phenotype | Molecular biology | Dermatitis | Index Medicus | Dermatitis, Atopic | Calcium | Calcitriol | Retinoid X Receptor alpha | Retinoids | Life Sciences | Retinoid X Receptor beta | Receptors, Retinoic Acid | Biochemistry, Molecular Biology | Vitamins | Dermatologic Agents | Receptors, Calcitriol | Biological Sciences
Journal Article
Journal of the American Academy of Dermatology, ISSN 0190-9622, 2007, Volume 56, Issue 1, pp. 31.e1 - 31.e15
Background Previous studies of infliximab in psoriasis have demonstrated rapid improvement with induction therapy and sustained response with regularly... 
Dermatology | RHEUMATOID-ARTHRITIS | LOCALIZATION | TUMOR-NECROSIS-FACTOR | THERAPY | PHASE-III | DOUBLE-BLIND | METHOTREXATE | PLACEBO-CONTROLLED TRIAL | INDUCTION | FACTOR-ALPHA | DERMATOLOGY | Tuberculosis - epidemiology | Neoplasms - etiology | United States | Humans | Immunosuppressive Agents - pharmacokinetics | Immunosuppressive Agents - therapeutic use | Middle Aged | Antibodies, Monoclonal - adverse effects | Tuberculosis - etiology | Antibodies, Monoclonal - therapeutic use | Male | Infliximab | Arthritis, Psoriatic - drug therapy | Adult | Female | Surveys and Questionnaires | Antibodies, Monoclonal - immunology | Immunosuppressive Agents - administration & dosage | Severity of Illness Index | Psoriasis - drug therapy | Double-Blind Method | Drug Administration Schedule | Lupus Erythematosus, Systemic - epidemiology | Europe | Antibodies, Monoclonal - pharmacokinetics | Psoriasis - psychology | Treatment Outcome | Cross-Over Studies | Canada | Antibodies, Monoclonal - administration & dosage | Immunosuppressive Agents - immunology | Quality of Life | Immunosuppressive Agents - adverse effects | Patients - psychology | Lupus Erythematosus, Systemic - chemically induced | Infusions, Intravenous | Neoplasms - epidemiology | Psoriasis | Formulae, receipts, prescriptions | Dermatologic agents | Drug therapy | Comparative analysis | Index Medicus
Journal Article
Journal Article
Journal Article
Journal Article
Journal Article